Employees: 03 (2023.0)Legal category: 5785Size: PMECreation date: 2000-04-01 (26 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: HAZEBROUCK (59190), Nord
PHARMACIE DE LA HAUTE LOGE : revenue, balance sheet and financial ratios
PHARMACIE DE LA HAUTE LOGE is a French company
founded 26 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in HAZEBROUCK (59190),
this company of category PME
shows in 2025 a revenue of 2.4 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DE LA HAUTE LOGE (SIREN 430460790)
Indicator
2025
2024
2023
2022
2022
2021
2020
2019
2018
2017
2016
Revenue
2 418 460 €
2 401 578 €
2 246 750 €
2 302 760 €
2 838 211 €
2 160 463 €
1 905 057 €
2 001 757 €
1 937 601 €
1 791 118 €
1 434 371 €
Net income
117 369 €
99 046 €
80 302 €
159 862 €
211 250 €
122 904 €
73 892 €
116 571 €
161 309 €
142 709 €
-37 094 €
EBITDA
164 448 €
134 049 €
108 454 €
229 715 €
281 853 €
172 279 €
111 917 €
155 662 €
225 071 €
265 089 €
-54 862 €
Net margin
4.9%
4.1%
3.6%
6.9%
7.4%
5.7%
3.9%
5.8%
8.3%
8.0%
-2.6%
Revenue and income statement
In 2025, PHARMACIE DE LA HAUTE LOGE achieves revenue of 2.4 M€. Over the period 2016-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +6.0%. Vs 2024: +1%. After deducting consumption (1.7 M€), gross margin stands at 713 k€, i.e. a rate of 29%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 164 k€, representing 6.8% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 117 k€, i.e. 4.9% of revenue. This profit can be retained or distributed to shareholders.
Revenue (2025)
?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production
2 418 460 €
Gross margin (2025)
?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed
713 314 €
EBITDA (2025)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
164 448 €
EBIT (2025)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
150 584 €
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
117 369 €
EBITDA margin (2025)
?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability 5-10% : Average < 5% : Low
6.8%
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 18%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 69%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.5 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 4.8% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
17.982%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
68.782%
Cash flow / Revenue (2025)
?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates
4.809%
Repayment capacity (2025)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
1.549
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE DE LA HAUTE LOGE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2022
2023
2024
2025
Debt ratio
0.0
7.25
11.544
14.27
14.742
17.32
15.528
17.199
18.155
18.32
17.982
Financial autonomy
78.91
75.919
72.744
73.951
72.524
70.576
54.761
72.127
68.878
67.263
68.782
Repayment capacity
0.0
0.534
0.804
1.309
1.882
1.451
0.777
1.15
2.351
1.85
1.549
Cash flow / Revenue
-2.443%
7.968%
8.02%
5.875%
4.325%
5.831%
7.58%
7.111%
3.524%
4.142%
4.809%
Sector positioning
Debt ratio
17.982025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good
In 2025, the debt ratio of PHARMACIE DE LA HAUTE LOGE (17.98) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
68.78%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good
In 2025, the financial autonomy of PHARMACIE DE LA HAUTE LOGE (68.8%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
1.55 years2025
2023
2024
2025
Q1: 0.51 years
Med: 2.46 years
Q3: 6.17 years
Good
In 2025, the repayment capacity of PHARMACIE DE LA HAUTE LOGE (1.55) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 171.62. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.0x. Danger: operating income does not cover interest charges, unsustainable situation.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
171.617
Interest coverage (2025)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable 1.5-3 : Acceptable < 1.5 : Risk
0.01
Liquidity indicators evolution PHARMACIE DE LA HAUTE LOGE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2022
2023
2024
2025
Liquidity ratio
187.887
165.018
158.584
210.637
187.19
202.953
142.402
228.665
175.285
164.497
171.617
Interest coverage
-0.018
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.001
0.01
Sector positioning
Liquidity ratio
171.622025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Average
In 2025, the liquidity ratio of PHARMACIE DE LA HAUTE LOGE (171.62) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
0.01x2025
2023
2024
2025
Q1: 0.0x
Med: 1.91x
Q3: 5.98x
Average
In 2025, the interest coverage of PHARMACIE DE LA HAUTE LOGE (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 8 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 38 days. Favorable situation: supplier credit is longer than customer credit by 30 days. Inventory turnover is 37 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 45 days of revenue, i.e. 301 k€ to permanently finance.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
300 566 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
8 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
38 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
37 j
WCR in days of revenue (2025)
?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management
45 j
WCR and payment terms evolution PHARMACIE DE LA HAUTE LOGE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2022
2023
2024
2025
Operating WCR
304 675 €
240 708 €
205 347 €
239 050 €
247 981 €
249 814 €
345 524 €
298 415 €
272 418 €
293 809 €
300 566 €
Inventory turnover (days)
46
42
41
44
43
38
31
38
39
37
37
Customer payment term (days)
6
4
6
8
7
6
63
8
8
8
8
Supplier payment term (days)
67
54
47
35
43
45
31
37
38
45
38
Positioning of PHARMACIE DE LA HAUTE LOGE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE DE LA HAUTE LOGE is estimated at
1 447 957 €
(range 897 526€ - 2 017 068€).
With an EBITDA of 164 448€, the sector multiple of 7.7x is applied.
The price/revenue ratio is 0.61x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
897k€1447k€2017k€
1 447 957 €Range: 897 526€ - 2 017 068€
NAF 5 année 2025
Valuation detail by method
Ajustez les pondérations selon votre analyse
EBITDA Multiple50%
164 448 €×7.7x
Estimation1 269 589 €
640 248€ - 1 848 256€
Revenue Multiple30%
2 418 460 €×0.61x
Estimation1 467 598 €
1 081 204€ - 1 692 780€
Net Income Multiple20%
117 369 €×15.9x
Estimation1 864 421 €
1 265 205€ - 2 925 533€
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DE LA HAUTE LOGE with other companies in the same sector:
Frequently asked questions about PHARMACIE DE LA HAUTE LOGE
What is the revenue of PHARMACIE DE LA HAUTE LOGE ?
The revenue of PHARMACIE DE LA HAUTE LOGE in 2025 is 2.4 M€.
Is PHARMACIE DE LA HAUTE LOGE profitable?
Yes, PHARMACIE DE LA HAUTE LOGE generated a net profit of 117 k€ in 2025.
Where is the headquarters of PHARMACIE DE LA HAUTE LOGE ?
The headquarters of PHARMACIE DE LA HAUTE LOGE is located in HAZEBROUCK (59190), in the department Nord.
Where to find the tax return of PHARMACIE DE LA HAUTE LOGE ?
The tax return of PHARMACIE DE LA HAUTE LOGE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DE LA HAUTE LOGE operate?
PHARMACIE DE LA HAUTE LOGE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart